Shattuck Labs, Inc. ( (STTK) ) has released its Q3 earnings. Here is a breakdown of the information Shattuck Labs, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shattuck Labs, Inc. is a biotechnology company based in Austin, Texas, specializing in the development of treatments for inflammatory and immune-mediated diseases, with a focus on innovative protein engineering. In its latest earnings report for the quarter ending September 30, 2025, Shattuck Labs highlighted a decrease in net loss compared to the previous year, despite a decline in revenue from collaborations. The company reported a net loss of $10.1 million for the quarter, an improvement from the $16.7 million loss in the same period last year, attributed to reduced research and development expenses. Shattuck Labs’ cash and cash equivalents stood at $42.5 million, with total assets increasing to $100.3 million, reflecting strategic financial management. Looking ahead, Shattuck Labs remains focused on advancing its pipeline of product candidates, with management expressing confidence in the company’s ability to sustain operations for the next twelve months, despite the challenging global economic environment.